BAXDELA

Shares of Melinta Therapeutics Inc (NASDAQ: MLNT) shares were gaining more than 200% Wednesday, but a Jefferies analyst said the move is "overdone." The Analyst David Hoang maintained a Hold rating on Melinta Therapeutics with an unchanged $5 price target. The Thesis...

Melinta Therapeutics (NASDAQ: MLNT) shares are trading higher after the company said the FDA accepted a supplemental New Drug Application (sNDA) for priority review of its BAXDELA sNDA for the treatment of community acquired bacterial pneumonia. "Due to the rise of antibiotic resistance...